[go: up one dir, main page]

WO2013038195A3 - Compositions de nanoparticules pharmaceutiques - Google Patents

Compositions de nanoparticules pharmaceutiques Download PDF

Info

Publication number
WO2013038195A3
WO2013038195A3 PCT/GB2012/052272 GB2012052272W WO2013038195A3 WO 2013038195 A3 WO2013038195 A3 WO 2013038195A3 GB 2012052272 W GB2012052272 W GB 2012052272W WO 2013038195 A3 WO2013038195 A3 WO 2013038195A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticle compositions
pharmaceutical nanoparticle
pharmaceutical
ocular
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2012/052272
Other languages
English (en)
Other versions
WO2013038195A2 (fr
Inventor
Francesca CRAWFORD
Philip Gunning
David HERMANS
Deepak Thassu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALTACOR Ltd
Original Assignee
ALTACOR Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALTACOR Ltd filed Critical ALTACOR Ltd
Priority to EP12762374.2A priority Critical patent/EP2755659A2/fr
Priority to CN201280044324.4A priority patent/CN103930115A/zh
Priority to CA2845673A priority patent/CA2845673A1/fr
Publication of WO2013038195A2 publication Critical patent/WO2013038195A2/fr
Publication of WO2013038195A3 publication Critical patent/WO2013038195A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation de nanoparticules d'antagonistes glucocorticoïdes pour le traitement de pathologies oculaires et non-oculaires, ainsi que des compositions les contenant et leurs procédés de préparation.
PCT/GB2012/052272 2011-09-13 2012-09-13 Compositions de nanoparticules pharmaceutiques Ceased WO2013038195A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP12762374.2A EP2755659A2 (fr) 2011-09-13 2012-09-13 Compositions de nanoparticules pharmaceutiques
CN201280044324.4A CN103930115A (zh) 2011-09-13 2012-09-13 药物纳米粒组合物
CA2845673A CA2845673A1 (fr) 2011-09-13 2012-09-13 Compositions de nanoparticules pharmaceutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534248P 2011-09-13 2011-09-13
US61/534,248 2011-09-13

Publications (2)

Publication Number Publication Date
WO2013038195A2 WO2013038195A2 (fr) 2013-03-21
WO2013038195A3 true WO2013038195A3 (fr) 2013-07-04

Family

ID=46889367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/052272 Ceased WO2013038195A2 (fr) 2011-09-13 2012-09-13 Compositions de nanoparticules pharmaceutiques

Country Status (4)

Country Link
EP (1) EP2755659A2 (fr)
CN (1) CN103930115A (fr)
CA (1) CA2845673A1 (fr)
WO (1) WO2013038195A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554126B2 (en) 2017-12-15 2023-01-17 Georgetown University Methods of treating residual lesions of vascular anomalies

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017001863A (es) 2014-08-13 2017-07-17 Univ Johns Hopkins Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
WO2023033900A1 (fr) * 2021-09-06 2023-03-09 Slayback Pharma Llc Compositions pharmaceutiques de mifépristone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084637A2 (fr) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Nouveaux procedes et nouvelle composition d'administration de macromolecules par voie orale
WO2007083145A1 (fr) * 2006-01-19 2007-07-26 Summit (Cambridge) Limited Traitement des états pathologiques oculaires et des effets secondaires systémiques des glucocorticoïdes
US20100105643A1 (en) * 2008-10-27 2010-04-29 Soll David B Ophthalmic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090798A (en) 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
CA2620346A1 (fr) 2005-08-25 2007-03-01 Psivida Inc. Regulation d'une elevation de pression intra-oculaire induite
EP2385824A2 (fr) 2009-01-06 2011-11-16 Pharmanova, Inc. Préparations pharmaceutiques nanoparticulaires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084637A2 (fr) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Nouveaux procedes et nouvelle composition d'administration de macromolecules par voie orale
WO2007083145A1 (fr) * 2006-01-19 2007-07-26 Summit (Cambridge) Limited Traitement des états pathologiques oculaires et des effets secondaires systémiques des glucocorticoïdes
US20100105643A1 (en) * 2008-10-27 2010-04-29 Soll David B Ophthalmic composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI V H K ET AL: "Ocular drug delivery of progesterone using nanoparticles", JOURNAL OF MICROENCAPSULATION, TAYLOR AND FRANCIS, BASINGSTOKE, GB, vol. 3, no. 3, 1 January 1986 (1986-01-01), pages 213 - 218, XP009166491, ISSN: 0265-2048 *
W HE ET AL: "Improved bioavailability of orally administered mifepristone from PLGA nanoparticles", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 334, no. 1-2, 4 April 2007 (2007-04-04), pages 173 - 178, XP055049805, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2006.10.025 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554126B2 (en) 2017-12-15 2023-01-17 Georgetown University Methods of treating residual lesions of vascular anomalies

Also Published As

Publication number Publication date
EP2755659A2 (fr) 2014-07-23
CA2845673A1 (fr) 2013-03-21
CN103930115A (zh) 2014-07-16
WO2013038195A2 (fr) 2013-03-21

Similar Documents

Publication Publication Date Title
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX350589B (es) Copolimeros funcionales pla-peg, las nanoparticulas de los mismos, su preparacion y su uso para la administracion dirigida de farmacos e imagenologia.
WO2011103202A3 (fr) Modulateurs du récepteur des androgènes et leurs utilisations
HK1212701A1 (zh) 恩杂鲁胺制剂
MX349004B (es) Nuevos compuestos.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2014031610A8 (fr) Procédés permettant de traiter ou d'empêcher l'asthme par administration d'un antagoniste du récepteur à l'interleukine 4 (il-4r)
GB201118656D0 (en) New compounds
WO2012177844A3 (fr) Composés d'imidazopyridinyle-aminopyridine substitués
MX366899B (es) Nuevos compuestos.
WO2012106393A3 (fr) Withanolide isolé à partir de physalis longifolia et ses analogues et procédés d'utilisation
WO2012080926A3 (fr) Anticorps anti-notch1
EP4414376A3 (fr) Nouveau depsipeptide et ses utilisations
HK1206393A1 (en) Compositions and methods for diagnosis and treatment of pervasive developmental disorder
WO2014066799A3 (fr) Modulateurs du récepteur des androgènes androgéno-résistant
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
HK1200366A1 (en) Pharmaceutical compositions and methods of use of 4-pregenen-11ss-17-21-triol-3,20-dione derivatives
WO2011129936A3 (fr) Compositions et procédés pour la prévention et le traitement du cancer
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
WO2016011049A3 (fr) Compositions et procédés pour le traitement de maladies à l'aide de composés distribués sous forme de nanoparticules
WO2013134534A3 (fr) Formes à l'état solide de cabazitaxel et procédés pour les préparer
WO2014068586A3 (fr) Compositions orales solides de tolvaptan
WO2013016205A3 (fr) Compositions et méthodes pour réduire l'incidence de troubles digestifs chez des équidés
WO2012040331A3 (fr) Nanoparticules multicouches
WO2013038195A3 (fr) Compositions de nanoparticules pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12762374

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2845673

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012762374

Country of ref document: EP